Scientific context only. Not medical advice, not a recommendation to use.
At a glance
Synthetic hexapeptide marketed as a topical anti-wrinkle ingredient (e.g. by Lipotec/Lubrizol). Mechanism modelled on the SNAP-25-blocking action of botulinum toxin, but with substantially lower potency and without intramuscular effect. EU-compliant as a cosmetic ingredient (CosIng), not approved as a medicine.
Researched for
Reduction of expression wrinkles (topical cosmetics)Modulation of SNAP-25-mediated neurotransmitter release in vitro
Official status
US: Unapproved
No FDA medicines approval. Marketable as a cosmetic ingredient without prior FDA approval; FDA oversees safety and efficacy claims.
Argireline is a synthetic hexapeptide whose sequence corresponds to the N-terminus of the SNAP-25 protein. In vitro it has been shown to competitively inhibit SNARE complex formation (necessary for vesicle fusion in neurotransmitter release). Topical application is intended — given very limited skin permeation — to attenuate cholinergic signalling at the neuromuscular endplate. The effect is orders of magnitude weaker than intramuscular botulinum toxin; the clinical translatability of the in-vitro observations to the skin microenvironment is contested.
02
Evidence at a glance
Reading note. The distribution shows on which evidence tier each observation sits. Strong colours mark stronger evidence — weaker tiers are deliberately visible, not hidden.
3 observations · 2 tiers
Human trial
1
In vitro
2
03
What the studies show
Human trial
Mensch
Blanes-Mira C. et al. 2002
Visual reduction of wrinkle depth in dynamic areas (forehead, periorbital) reported in industry-sponsored cosmetic studies
What does NOT follow: Studies predominantly from manufacturer labs (Lipotec) without independent replication in larger cohorts. Effect sizes small and assessed by skin topography measurement, not by blinded rater scales.
In vitro
Zellfreies System
Competitive inhibition of SNAP-25 vesicle fusion documented in cell-free assays
What does NOT follow: Mechanistic finding under optimised conditions; intact skin forms a permeation barrier making it questionable whether relevant concentrations reach the site of action.
In vitro
Franz-Zell, ex-vivo-Haut
Skin permeation studies show low and highly formulation-dependent penetration into deeper skin layers
What does NOT follow: Results vary widely between studies and formulations. Permeation into muscle (where SNAP-25 inhibition would matter) is not established.
04
Where studies disagree
Open question
Is the topical anti-wrinkle effect of argireline independently replicable?
Independent academic studies are scarce and mostly find only small, often not clinically relevant effects.
CURRENT STATE · The evidence base is dominated by industry studies. A systematic Cochrane assessment is pending.
05
Pharmacokinetics
No robust pharmacokinetic human data available. A model curve is not invented.
06
Routes of administration in the literature
Which routes of administration the available studies describe — neutral reporting, not a usage guide.
Topical
In all cosmetic studies applied to the skin as cream or lotion.
07
Known adverse events from studies
Factual reporting of what studies observed. Not a safety statement for individual use.
Human trial
Skin irritation
Manufacturer studies describe mild, transient local reactions; allergic sensitisations are documented in isolated cases.
selten
07b
Interactions & combinations
Documented interactions and contraindications from studies, prescribing information and guidelines. Where no data exists, this is stated.
Reporting of risks, NOT a combination guide. The absence of an entry does not mean „safe to combine“ but „not sufficiently studied“.
No documented interactions recorded
We have not yet found robustly documented interactions for this peptide. This does NOT mean none exist — the data is limited.
08
Risks & hygiene aspects in the literature
What regulatory and scientific literature reports on risks, sterility and identity in non-pharmaceutical sources — descriptive, not a hygiene guide.
Claims caution
Marketing comparisons with botulinum toxin are regulatorily sensitive: cosmetic products must not suggest pharmaceutical effects. Effect sizes in independent studies are small to non-reproducible.
10
Anecdotal observations
Weakest evidence tier — not supported by studies
Reading note. This section gathers popular claims from communities and forums. They are explicitly marked as weakest-tier evidence. Unblinded self-reports are particularly prone to placebo, recall and confirmation biases.
Why no amounts or protocols are listed here. We deliberately show only WHAT communities report — not in what amount or how it is used. Anecdotal "doses" or "biohacker protocols" are neither verified nor standardised nor safe; publishing them would be a usage guide, which we do not provide on principle. Specific amounts belong in a conversation with a doctor, not in a forum.
In beauty communities argireline-containing cream is advertised as 'topical botox'.
very widespread
Not supported by studies: This claim is mechanistically misleading and regulatorily problematic. Botulinum toxin acts intramuscularly; argireline barely permeates beyond the stratum corneum. In-vivo effect sizes in independent studies are small and overlap with high-quality moisturisers.
11
Legal status by country
Country
Status
Note
Checked
EU
Unapproved
EU CosIng-listed as a cosmetic ingredient (INCI: Acetyl Hexapeptide-8). Not approved as a medicine; any pharmaceutical efficacy claim on cosmetics would be regulatory non-compliant.
2026-05-22
United States
Unapproved
No FDA medicines approval. Marketable as a cosmetic ingredient without prior FDA approval; FDA oversees safety and efficacy claims.
2026-05-22
Germany
Unapproved
Follows EU cosmetic regulation; not approved as a medicine.
2026-05-22
12
Reconstitution calculator
Pure mg/mL maths — works like a calculator. Not a usage recommendation.
Peptides ship as a dry powder. Once dissolved in a liquid (reconstitution), this calculator answers a single question: how much substance is in one millilitre of solution afterwards?
1Enter the vial's substance amount (printed on the label).
2Enter how much solvent you add.
3Result = concentration in mg per mL.
Printed on the label
/
Liquid you add
=
2.50
mg / mL
5 mg in 2 mL gives 2.50 mg/mL — each millilitre contains 2.50 mg of substance.